our science

HORMONE RECEPTOR
POSITIVE CANCERS

 
 
Science.jpg

A STEP FORWARD.

Context Therapeutics is dedicated to creating new medicines to treat hormone-responsive (HR+) cancers. We are building Context Therapeutics to become a global company that will discover, develop and market groundbreaking cancer treatments to patients around the world, eliminating the fear that comes with a cancer diagnosis. Context’s lead program is Apristor® , an investigational Phase 2 drug that is being developed for progesterone receptor positive (PR+) metastatic breast cancer.
Presentation4 copy.jpg
 
nci-vol-2289-300.jpg

Why HR+ Cancer?

Breast, prostate, and gastrointestinal cancers are poorly addressed and result in >100,000 deaths per year in the United States.

The rapid advances in the field of immune-oncology ("IO") have not trickled down to HR+ cancers.

The underlying drivers of HR+ cancer growth (hormones and their associated regulatory proteins) are well understood relative to other cancers.
Treatment.jpg

The Unmet Need

Most current antihormonals are dual agonist/antagonists. There is a need for pure antagonists.

Identification of novel drug targets beyond androgen receptor (AR) and estrogen receptor (ER).

A new generation (the "3rd Gen") of companies developing HR+ targeting agents has emerged to address this unmet need.